Kathleen Moore

Kathleen Moore led the PRIMA trial establishing niraparib as first-line maintenance therapy in ovarian cancer, including HRD-high patients, at the University of Oklahoma. Her work has been central to defining HRD as a clinically actionable biomarker in ovarian cancer. She continues to investigate novel combinations and sequencing strategies involving PARP inhibitors and immunotherapy. She is a frequent educator and speaker on ovarian cancer management and biomarker-guided therapy.